F D C

F D C FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of F D C (FDC.NS) as of Oct 27, 2026 is 82.78 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 41.73 % — a change of 98.37% (higher).

FCF Conversion

82.78 %

YoY

98.37%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of F D C is 2025 82.78 % . FCF Conversion Rate (FCF/EBITDA) of F D C was 2024 41.73 % . It decreases by 98.37% higher compared to the previous year.

The F D C FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
65.03 INR
Jan 1, 2019
41.05 INR
Jan 1, 2020
91.36 INR
Jan 1, 2021
47.97 INR
Jan 1, 2022
13.45 INR
Jan 1, 2023
21.55 INR
Jan 1, 2024
41.73 INR
Jan 1, 2025
82.78 INR
The F D C FCF Conversion history
YEARFCF ConversionYoY
82.78 %+98.37%
41.73 %+93.62%
21.55 %+60.23%
13.45 %-71.96%
47.97 %-47.50%
91.36 %+122.55%
41.05 %-36.87%
65.03 %-4.50%
68.09 %-185.66%
-79.49 %-255.64%
51.07 %-4,894.90%
-1.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

FCF Conversion Rate (FCF/EBITDA) of F D C is 82.78 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of F D C changed from 41.73 % to 82.78 %, representing a 98.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) F D C since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s F D C with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — F D C

All Key Metrics — F D C